Procedure Type
Non SurgicalProcedure Duration
1 - 3 HoursHospital Stay (Days)
5-6 daysInduction therapy refers to the initial phase of treatment used to reduce or eliminate a disease—most commonly in cases of cancer, autoimmune disorders, or organ transplantation. Its primary goal is to bring the disease under control quickly and aggressively, often by using a combination of high-dose medications or therapies. In cancer, for example, induction therapy aims to shrink or eradicate tumors. In organ transplantation, it’s used to prevent the body from rejecting the new organ by suppressing the immune system early on.
Induction therapy is typically required when a disease is aggressive or advanced, or when a swift and powerful response is needed. It is most frequently used in treating acute leukemias, lymphomas, multiple myeloma, and in preparing patients for organ transplants like kidney or liver transplantation. It may also be used in severe autoimmune diseases like lupus or multiple sclerosis when other treatments fail to provide adequate control.
In oncology, induction therapy is often the first line of defense, especially in blood cancers like acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). It usually involves a high-intensity chemotherapy regimen, and in some cases, radiation or targeted therapy. The aim is to put the disease into remission by destroying as many cancer cells as possible before moving to consolidation or maintenance therapy phases.
For organ transplant patients, induction therapy is used at the time of the transplant to prevent early immune rejection of the new organ. It involves administering powerful immunosuppressive agents, such as monoclonal antibodies or interleukin inhibitors, which blunt the recipient’s immune response. This phase is crucial for establishing tolerance to the new organ and reducing the risk of acute rejection.
The specific medications used in induction therapy depend on the disease being treated. In cancer, these may include chemotherapy agents like cytarabine, daunorubicin, or vincristine. For transplant patients, drugs such as basiliximab, antithymocyte globulin (ATG), or alemtuzumab are commonly used. These drugs are selected based on the individual’s condition, risk factors, and response to previous treatments.
PRINCIPAL DIRECTOR & CHIEF HEMATOLOGY
PRINCIPAL DIRECTOR & PAEDIATRIC HEMATOLOGY
Director, Department of Hemato-Oncology & Bone Marrow Transplant
The duration of induction therapy can vary significantly based on the medical condition. In some leukemia cases, it may last several weeks, during which the patient is often hospitalized due to the intensity of treatment. In transplantation, induction therapy typically lasts for a few days around the time of surgery. The timing is carefully planned to balance effectiveness with safety.
Because induction therapy is aggressive, it often comes with significant side effects. These can include nausea, vomiting, low blood counts, fatigue, increased risk of infections, and organ toxicity. In transplant patients, the immunosuppressive nature of the therapy can increase susceptibility to infections and may cause metabolic complications. Patients undergoing induction therapy require close monitoring and supportive care.
Gurugram, India
Gurugram, India
Gurugram, India
Honest Guidance, Reliable Support, Seamless Journeys.
Provide Us
Reports
Get Medical
Opinions
Pre-Arrival
Arrangements
Visa
Support
Assistance in
Treatments
Fly back and
Follow Up